Evidence map›Paper›PMID 30100908›Full record

ArticleFrontiers in immunology2018

β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids

Thomas Klag, Maria Thomas, Dirk Ehmann, Lioba Courth, Daniela Mailänder-Sanchez, Thomas S Weiss, Rania Dayoub, Kerstin Abshagen, Brigitte Vollmar, Wolfgang E Thasler and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Thomas KlagDepartment of Internal Medicine I, University of Tübingen, Tübingen, Germany.
Maria ThomasDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany.
Dirk EhmannDepartment of Internal Medicine I, University of Tübingen, Tübingen, Germany.
Lioba CourthDepartment of Internal Medicine I, University of Tübingen, Tübingen, Germany.
Daniela Mailänder-SanchezDepartment of Internal Medicine I, University of Tübingen, Tübingen, Germany.
Thomas S WeissUniversity Children Hospital (KUNO), Regensburg University Hospital, Regensburg, Germany.
Rania DayoubUniversity Children Hospital (KUNO), Regensburg University Hospital, Regensburg, Germany.
Kerstin AbshagenRudolf-Zenker-Institute for Experimental Surgery, University Medicine Rostock, Rostock, Germany.
Brigitte VollmarRudolf-Zenker-Institute for Experimental Surgery, University Medicine Rostock, Rostock, Germany.
Wolfgang E ThaslerDepartment of Surgery, Grosshadern Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
Eduard F StangeDepartment of Internal Medicine I, University of Tübingen, Tübingen, Germany.
Christoph P BergDepartment of Internal Medicine I, University of Tübingen, Tübingen, Germany.
Nisar P MalekDepartment of Internal Medicine I, University of Tübingen, Tübingen, Germany.
Ulrich M ZangerDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany.
Jan WehkampDepartment of Internal Medicine I, University of Tübingen, Tübingen, Germany.
University of Tübingen · DEDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEUniversity Hospital Regensburg · DEUniversity of Rostock · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & aims: Knowledge about innate antimicrobial defense of the liver is limited. We investigated hepatic expression and regulation of antimicrobial peptides with focus on the human beta defensin-1 (hBD-1). Methods: Radial diffusion assay was used to analyze antimicrobial activity of liver tissue. Different defensins including hBD-1 and its activator thioredoxin-1 (TXN) were analyzed in healthy and cholestatic liver samples by qPCR and immunostaining. Regulation of hBD-1 expression was studied Results: We found strong antimicrobial activity of liver tissue against Conclusion: hBD-1 is prominently expressed in hepatocytes. It is induced during cholestasis through bilirubin and BAs, mediated by CAR and especially FXR. Reduction by TXN activates hBD-1 to a potential key player in innate antimicrobial defense of the liver.

Indexed as

Adenosine MonophosphateAnimalsbeta-DefensinsBile Acids and SaltsBilirubinCholestasisConstitutive Androstane ReceptorDisease Models, AnimalGene ExpressionHepatocytesHumansLiverMiceReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearAdenosine Monophosphatebeta-DefensinsBile Acids and SaltsBilirubinConstitutive Androstane ReceptorDEFB1 protein, humanReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and Nuclearantimicrobial peptidesbilirubincholestasishepatocyteshuman β-defensin-1

Identifiers

PMID30100908
PMCPMC6072844
OpenAlexW2883148490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.